Skip to main content
SpringerLink
Log in

The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

The BTA Test is an adjunctive test for the diagnosis and management of bladder cancer. For estimation of its potential in the management of patients with transitional-cell cancer (TCC) a review of published results was undertaken. Three prospective studies were analyzed, in which a total of 699 patients with a history of TCC were enrolled. The BTA Test was performed on voided urine and compared with either voided-urine or bladder-wash cytologic analysis in a blinded fashion. In all three studies the sensitivity of the BTA Test was more than double that of cytology, irrespective of whether the cytologic analysis was performed on voided or bladder-wash samples. The third study also included an additional 225 patients undergoing evaluation for hematuria, and TCC was found in 67 cases. The BTA Test detected 70% of these tumors, whereas cytology detected only 25%. The BTA Test is a simple, rapid test that can diagnose a substantial percentage of patients having new or recurrent bladder TCC. Its complete role in the management of such patients remains to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Badalament RA, Kimmel M, Gay H, Cibas ES, Whitmore WF Jr, Herr HW, Fair WR, Melamed MR (1987) The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma. Cancer 59: 2078–2085

    Google Scholar 

  2. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang NJ, Hayden CL (1996) Urinary nuclear matrix (NMP22) as a marker for transitional cell carcinoma of the urinary tract. J Urol 156: 1280–1285

    Google Scholar 

  3. D'Hallewin M-A, Baert L (1996) Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 155: 475–476

    Google Scholar 

  4. deVere White RW, Deitch AA, Tesluk H, Blumenstein B, Lowe BA, Sagalowsky Al, Smith JA Jr, Schellhammer PF, Stanisic TH, Grossman HB, Messing E (1996) Prognostic significance of DNA ploidy in Ta/T1 bladder cancer: A Southwest Oncology Group study. Urol Oncol 2: 27–34

    Google Scholar 

  5. Jordan AM, Weingarten J, Murphy WM (1987) Transitional cell neoplasm of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 60: 2766–2774

    Google Scholar 

  6. Leyh H, Mazeman E, Hall RR, Bennett AH (1996) Results of a European multicenter trial comparing the Bard BTA Test to urine cytology in patients suspected to having bladder cancer. J Urol 155: 492A

  7. Murphy WM (1990) Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 21: 886–896

    Google Scholar 

  8. National Bladder Cancer Collaborative Group A (1977) Surveillance, initial assessment, and subsequent progress of patients with superficial bladder cancer in a prospective longitudinal study. Cancer Res 37: 2907–2910

    Google Scholar 

  9. Sarosdy MF (1992) Principles of intravesical chemotherapy and immunotherapy. Urol Clin North Am 19: 509–510

    Google Scholar 

  10. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA (1995) Results of a multicenter trial using the BTA Test to monitor and diagnose recurrent bladder cancer. J Urol 154: 379–384

    Google Scholar 

  11. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363–367

    Google Scholar 

  12. Zein T, Wajsman Z, Englander LS, Gamarra M, Lopez C, Huben RP, Pontes JE (1984) Evaluation of bladder washing and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa. J Urol 132: 670–671

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas Health Science Center, 7703 Floyd Curl Drive, 78284-7845, San Antonio, TX, USA

    Michael F. Sarosdy

Authors
  1. Michael F. Sarosdy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarosdy, M.F. The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 15, 103–106 (1997). https://doi.org/10.1007/BF02201980

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02201980

Keywords

Search

Navigation